Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Itama Ranoraya Tbk (IRRA.JK)
Jakarta, JK, ID
PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia. The company offers in vitro diagnostics products comprising rapid test and clinical laboratory; medical imaging products, including bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; cardiovascular, urology, and surgical products; and hospital supplies. It also provides cold chain management, such as cold room, bloodbank, and pharmaceutical refrigerator; critical care; and pharmaceutical supplements, as well as maternal and neonatal care products. In addition, the company leases office space. It sells its products under the oneject, Abbott, Terumo, Medtronic, HMD, BD, Vestfrost, Hemocue, Planmed, Sinmed, Balmed, Zepa, KSM CARE, Trisan Care, GEA, Hologic, IS, Avimac, RadmediX, MTS, and SMAM brands. PT Itama Ranoraya Tbk was founded in 1988 and is based in Jakarta Timur, Indonesia. PT Itama Ranoraya Tbk is a subsidiary of PT Global Dinamika Kencana.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.53% | -0.53% | -2.59% | -9.18% | -14.16% | -12.15% | -29.06% | -42.60% | -76.65% | -32.86% | -32.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Distribution: +5.6%+12.6% ★ Q1'26: +1.2% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+20.1% ★ Q1'26: +1.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+4.7% Q1'26: -49.3% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+9.2% ★ Q1'26: +10.2% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+6.3% ★ Q1'26: +5.3% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+2.4% Q1'26: +2.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×7.26× Q1'26: 9.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hendry Herman | Sales Director & Director | — | male |
| Heru Firdausi Syarif | President Director | — | male |
| Nanan Meinanta Lasahido | Corporate Secretary & Director | — | male |
| Roben Pontinus | Head of Internal Audit | — | — |
| Viertin Maretson Lumban Tobing | Corporate Secretary & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IRRA.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
